Clinical Trial Update: Lenvatinib (LEN) in Combination With Pembrolizumab (KEYtruda) in Subjects With Locally Advanced or Metastatic Non-clear Cell Renal Cell Carcinoma (The LENKYN Trial) [Phase 2]

View source ↗

Summary

A Phase 2 trial of lenvatinib plus pembrolizumab in locally advanced or metastatic non-clear cell renal cell carcinoma was terminated. Results have been posted …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-clear Cell Renal Cell Carcinoma
• Renal Cell Carcinoma

Drugs mentioned

• KEYTRUDA (PEMBROLIZUMAB)
• LENVIMA (lenvatinib)

Snippet

Sponsor: Washington University School of Medicine | Conditions: Renal Cell Carcinoma | Phase 2 | Status: TERMINATED | Results posted: 2025-03-21